Johnson & Johnson (JNJ) Tops Q2 EPS by 18c; raises forecast

Johnson & Johnson (NYSE: JNJ) reported Q2 EPS of $2.80, $0.18 better than the analyst estimate of $2.62. Revenue for the quarter came in at $25.53 billion versus the consensus estimate of $24.67 billion.

GUIDANCE:

Johnson & Johnson sees FY2023 EPS of $10.60-$10.70, versus the consensus of $10.65. Johnson & Johnson sees FY2023 revenue of $99.3-100.3 billion, versus the consensus of $98.96 billion.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in earl
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance